Table 1.
IBD patient demographics and clinical characteristics
| Total | N = 29 |
| Sex, n (%) | |
| Male | 16 (55) |
| Female | 13 (45) |
| Ethnicity, n (%) | |
| Hispanic | 12 (41) |
| Non-Hispanic | 17 (59) |
| Race, n (%) | |
| White | 24 (83) |
| Black | 3 (10) |
| Asian | 1 (3) |
| Other | 1 (3) |
| Current BMI, median | 25.3 |
| Current age, yr, median | 47 |
| Years of disease, yr, median | 17 |
| Current inflammation, n (%) | 12 (41) |
| Inflamed total SES-CD, median | 4.5 |
| Inflamed total Mayo, median | 2 |
| CD, n (%) | 17 (58) |
| Disease location, n (%) | |
| Ileum only | 7 (24) |
| Ileum and colon | 9 (31) |
| Colon only | 1 (3) |
| Disease behavior, n (%) | |
| Inflammatory | 12 (41) |
| Fibrostenotic | 7 (24) |
| Penetrating/perforating | 4 (14) |
| UC, n (%) | 12 (41) |
| Disease location, n (%) | |
| Pancolitis | 5 (17) |
| Left sided | 7 (24) |
| Disease severity, n (%) | |
| Mild | 3 (10) |
| Moderate | 9 (31) |
| Current medications, n (%) | |
| None | 2 (7) |
| Aminosalicylates | 6 (21) |
| Steroids | 0 (0) |
| Immunomodulators | 3 (10) |
| Biologics | 23 (79) |
| Anti-TNF | 12 (41) |
| Anti-integrin | 5 (17) |
| Anti-IL-12/23 | 5 (17) |
| JAK inhibitor | 1 (3) |
BMI, body mass index; CD, Crohn's disease; IBD, inflammatory bowel disease; IL, interleukin; JAK, Janus kinase; SES-CD, Simple Endoscopic Score for CD; TNF, tumor necrosis factor.